Policy changes Backwork has recorded, newest first. The most recent change on record is from October 24, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
86,510 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Temporarily Implanted Nitinol Device (iTind) for Benign Prostatic Hyperplasia | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Nipocalimab (e.g., Imaavy) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Genetic Test: Next-Generation Sequencing for the Assessment of Measurable Residual Disease | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | New-To-Market Medical Benefit Medication | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Neuromuscular Stimulation, Functional | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Remote Electrical Neuromodulation for Migraines | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Neurofeedback | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Nerve Conduction Studies (NCS), Electromyography (EMG) and Surface EMG (SEMG) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Nedosiran (e.g., Rivfloza) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Naxitamab-gqgk (e.g., Danyelza) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Navigated Transcranial Magnetic Stimulation | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Natalizumab (e.g., Tysabri) and Biosimilars | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Narsoplimab (e.g., Yartemlea) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Nadofaragene firadenovec-vncg (e.g., Adstiladrin) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Nab-Paclitaxel (e.g., Abraxane) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Myoelectric Prosthetic and Orthotic Components for the Upper Limb | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Myocardial Strain Imaging | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Multitarget Polymerase Chain Reaction Testing for Diagnosis of Bacterial Vaginosis (e.g., SureSwab, NuSwab) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Multiple Sleep Latency/Maintenance of Wakefulness Test | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Mucopolysaccharidoses Agents | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | MRI-Guided Focused Ultrasound (MRgFUS) Ablation | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Magnetic Resonance Imaging (MRI), Functional | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Magnetic Resonance Imaging (MRI), Cardiac Applications | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Magnetic Resonance Imaging (MRI), Breast | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Magnetic Resonance Imaging (MRI), Magnetic Resonance Imaging (MRI) Targeted Biopsy, and MRI-Ultrasound Fusion Biopsy for Prostate Cancer | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Mosunetuzumab-axgb (e.g. Lunsumio and Lunsumio Velo) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Monoclonal Antibodies for Treatment of Alzheimer Disease [Aducanumab (e.g., Aduhelm) and Lecanemab (e.g., Leqembi)] | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Genetic Test: Molecular Testing for Germline BRIP1, RAD51C, and RAD51D Variants Associated with Ovarian Cancer | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Molecular Testing in the Management of Pulmonary Conditions | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Mogamulizumab- kpkc (e.g., Poteligeo) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Mitomycin Intravesical Solution (e.g., Zusduri) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Mitomycin Gel (e.g., Jelmyto) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Mirvetuximab soravtansine-gynx (e.g. Elahere) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Mirikizumab-mrkz (e.g., Omvoh) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Minimally Invasive Treatment of Nasal Obstruction | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Minimally Invasive Lumbar Interbody Fusion | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Minimally Invasive Image-Guided Spinal Decompression for Spinal Stenosis | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Microwave Ablation of Tumors | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Microprocessor-Controlled Prosthesis and Orthosis for the Lower Limb | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Meniscal Allograft Transplantation and Synthetic Meniscal Implants | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Medical Technology Assessment, Non-Covered Services | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Measurement of Exhaled Nitric Oxide and Exhaled Breath Condensate the Diagnosis and Management of Asthma and Other Respiratory Disorders | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Measurement of Serum Antibodies to Infliximab, Adalimumab, Vedolizumab, and Ustekinumab | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Genetic Test: Multicancer Early Detection Testing | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Open and Thoracoscopic Approaches to Treat Atrial Fibrillation and Atrial Flutter (Maze and Related Procedures) | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Maximum Dosage and Frequency for Medical Benefit Drugs | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Risk-Reducing Mastectomy | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Mastectomy, Male Gynecomastia | New policy |
| Aug 2, 2026 | Arkansas Blue Cross and Blue Shield | Margetuximab-cmkb (e.g., Margenza) | New policy |